Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions

Pharmacogenomics Journal

Volumn 16, Issue 2, 2016, Pages 129-136

  Alagoz, O ^a   Durham, D ^b   Kasirajan, K ^c  

^a University of Wisconsin Madison   (United States)

^b Sage Neuroscience Center   (United States)

^c Animal Diagnostic Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG SAFETY; GENETIC ANALYSIS; HEALTH CARE COST; MEDICAL DECISION MAKING; MONTE CARLO METHOD; PHARMACOGENOMICS; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; SENSITIVITY ANALYSIS; ADULT; ADVERSE DRUG REACTION; AGED; COST BENEFIT ANALYSIS; ECONOMICS; GENETIC SCREENING; GENETICS; HUMAN; MARKOV CHAIN; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC TESTING; HUMANS; MARKOV CHAINS; MIDDLE AGED; MONTE CARLO METHOD;

EID: 84929677920     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2015.39     Document Type: Article

References (29)

1. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patientsExcess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301-306
2. De Smet PA, Denneboom W, Kramers C, Grol R. A composite screening tool for medication reviews of outpatients. Drugs Aging 2007; 24: 733-760
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-nalysis of prospective studies. JAMA 1998; 279: 1200-1205
4. Drummond MF, O'Brien BJ, Stoddart GL, Torrance W. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press: New York, NY, USA, 1998
5. Gold MR, Siegel J, Russell L, Weinstein M. Cost-effectiveness in Health and Medicine: Report of the Panel on Cost-effectiveness in Health and Medicine. Oxford University Press: New York, NY, USA, 1996
6. Heitjan D, Asch D, Ray R, Rukstalis M, Patterson F, Lerman C. Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. Pharmacogenomics J 2008; 8: 391-399
7. Perlis RH, Patrick A, Smoller JW, Wang PS. When is pharmacogenetic testing for antidepressant response ready for the clinic?. a cost-effectiveness analysis based on data from the STAR D Study. Neuropsychopharmacology 2009; 34: 2227-2236
8. Reese ES, Daniel Mullins C, Beitelshees AL, Onukwugha E. Cost-effectiveness of cytochrome p450 2c19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy 2012; 32: 323-332
9. Alagoz O, Hsu H, Schaefer AJ, Roberts MS. Markov decision processes: a tool for sequential decision making under uncertainty. Med Decis Making 2009; 30: 474-483
10. Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf 2010; 19: 901-910
11. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006; 296: 1858-1866
12. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365: 2002-2012
13. Epstein RS, Moyer TP, Aubert RE, Kane DJ, Xia F, Verbrugge RR et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study). J Am Coll Cardiol 2010; 55: 2804-2812
14. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. New England Journal of Medicine 2013; 369: 2283-2293
15. Damani SB, Topol EJ. The case for routine genotyping in dual-ntiplatelet therapy. J Am Coll Cardiol 2010; 56: 109-111
16. Cause of Death 1999-2010 on CDC WONDER Online Database, released 2012. Data are from the Multiple Cause of Death Files, 1999-2010, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Available at http://wonder.cdc.gov/ucd-icd10.html. 2014
17. Chyka PA. How many deaths occur annually from adverse drug reactions in the United States?. Am J Med 2000; 109: 122-130
18. Sarkar U, López A, Maselli JH, Gonzales R. Adverse drug events in US adult ambulatory medical care. Health Serv Res 2011; 46: 1517-1533
19. Bond C, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy 2006; 26: 601-608
20. Neumann PJ. Why dont Americans use cost-effectiveness analysis. Am J Manag Care 2004; 10: 308-312
21. Chou WH, Yan F-X, de Leon J, Barnhill J, Rogers T, Cronin M et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clinical Psychopharmacol 2000; 20: 246-251
22. World Health Organization (2014) Table: Threshold values for intervention costeffectiveness by Region. World Health Organization. Available at http://www.who. int/choice/costs/CER-levels/en/index.html. Accessed 7 November 2013
23. Food and Drug Administration (2014). FDA Adverse Events Reporting System (FAERS) Patient Outcomes by Year 2014. Available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070461.htm
24. Rennie D, Luft HS. Pharmacoeconomic analyses: making them transparent, making them credible. JAMA 2000; 283: 2158-2160
25. Wu C, Bell CM, Wodchis WP. Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments. Drug Safety 2012; 35: 769-781
26. Pfuntner A, Wier LM, Steiner C. Statistical brief #146 by Agency for Health Care Research and Quality: Costs for Hospital Stays in the United States, 2010. Agency for Health Care Policy and Research, Rockville, MD, USA, 2013. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf
27. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005; 43: 203-220
28. Centers for Disease Control Prevention (2013). CDC/NCHS National Hospital Discharge Survey, 2010. Number and rate of discharges from short-stay hospitals and days of care, with average length of stay and standard error, by selected firstlisted diagnostic categories: United States, 2010. Available at http://www.cdc.gov/nchs/data/nhsr/nhsr029.pdf
29. Agency for Healthcare Research and Quality (2011). Emergency Room Services-Mean and Median Expenses per Person With Expense and Distribution of Expenses by Source of Payment: United States. Medical Expenditure Panel Survey Household Component Data 2011. Available at: http://www.meps.ahrq.gov/mepsweb/surveycomp/household.jsp.